# Denali Therapeutics Inc. (DNLI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $22.28, market value $3.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Denali Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.3×**. The shares trade at 4.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.4%** (5-yr avg -10.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -50.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -44.8%**. Each dollar of assets produces -44.8% of profit.

## Growth
- **EPS growth (1 yr): -15.6%**. Earnings per share fell 15.6%.

## Financial health
- **Current ratio: 9.16** (quick 9.16). Current assets cover the next year's liabilities 9.16 times.
- **Altman Z-score: 16.78**. A Z-score of 16.78 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Denali Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (16 analysts). 16 analysts cover Denali Therapeutics Inc.; the consensus is strong_buy, with an average price target of $35.75 (+60% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 50.6%** (YTD 34.9%, 3-mo 14.1%). The shares are up 50.6% over twelve months including dividends.
- **From 52-week high: -18.4%** (77.1% above the low). Trading 18% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 35**. An RSI of 35 is neutral.
- **Beta (1 yr): 1.42** (volatility 57%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DNLI · Page: https://foliofundamentals.com/stocks/dnli

Not investment advice.